Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Recruiting · NCT05641831 · Registry updated 2026-01-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study | Clonal Cytopenia of Undetermined Significance | Recruiting | Phase 2 | 2026-01-02 | NCT05641831 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Uma Borate | 5 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| University of Miami | Miami | United States | 327 |
| UT Southwestern Medical Center at Dallas | Dallas | United States | 2 |
| Vanderbilt University Medical Center | Nashville | United States | 427 |
| Weill Cornell Medical College | New York | United States | 35 |